Thomas W. Beetham - 30 Oct 2023 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Chief Operating Officer
Signature
/s/ Lara Meisner, Attorney-in-Fact for Thomas Beetham
Issuer symbol
VRDN
Transactions as of
30 Oct 2023
Net transactions value
$0
Form type
4
Filing time
01 Nov 2023, 16:35:05 UTC
Previous filing
02 Dec 2022
Next filing
30 Sep 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Award $0 +474,400 $0.000000 474,400 30 Oct 2023 Common Stock 474,400 $13.02 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% on October 30, 2024 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date.